Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of DelNS1-2019-nCoV-RBD-OPT1 intranasal COVID-19 vaccine
PACTR202110872285345Phase 3Not yet recruiting
- Sponsor
- Wantai BioPharm
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing DelNS1-2019-nCoV-RBD-OPT1 intranasal vaccine with Placebo intranasal spray (2 arms). Primary endpoints: Protective efficacy against symptomatic COVID-19 and Safety. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
Pneucolin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202110872285345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202110872285345.